Yang Pengxiang, Yao Xiaomin, Tian Xue, Wang Yuehan, Gong Leilei, Yang Yumin, Jie Jing
Key Laboratory of Neuroregeneration of Jiangsu Province and Ministry of Education, Co-Innovation Center of Neuroregeneration, NMPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products, Nantong University, 226001, Nantong, PR China.
Engineering Research Center of Integration and Application of Digital Learning Technology, Ministry of Education, 100034, Beijing, PR China.
Mater Today Bio. 2025 Jan 22;31:101517. doi: 10.1016/j.mtbio.2025.101517. eCollection 2025 Apr.
Chimeric antigen receptor T-cell (CAR-T) therapy, which benefits from the perfect combination of gene editing techniques and antibody engineering, has shown outstanding clinical efficacy in hematological malignancies. Solid tumors present the next challenge due to their extremely complicated microenvironment and structural characteristics. Targeting efficiency and persistence are currently bottleneck issues in the clinical treatment of CAR-T. Beyond drugs and cytokines, biomaterials can modulate the immune response, assisting adoptive CAR-T cells in exerting their function. In this study, a supramolecular peptide hydrogel epitope vaccine was designed to serve as both a preparation medium and a reservoir for CAR-T cells. The self-assembling peptide formed a nanofiber scaffold through non-covalent interactions of amphiphilic amino acids and ion stabilizers. Firstly, the complementary peptide conjugated vaccine epitopes and CAR-T target sites were derived from different extracellular domains of the HER2 protein, and the combination treatment improved tumor antigen spreading and targeting efficiency. The epitope hydrogel promoted CAR-T cell proliferation, cytotoxic activity, and lymphocyte subpopulation transformation. Furthermore, the supramolecular peptide epitope vaccine encapsulated CAR-T (SPEV-CAR-T) induced endogenous humoral and cellular immune responses through a sustained release of the hydrogel and CAR-T cells, demonstrating superior anti-tumor effects in an in vivo mouse model. Most importantly, SPEV-CAR-T induced central memory cells in systemic immune tissues, addressing the poor persistence of single CAR-T therapy. The integration and complementation of active and passive immune responses in this all-in-one hydrogel epitope vaccine and CAR-T system facilitated a sequential succession of endogenous and exogenous immune responses, promoting persistent and specific tumor attack. SPEV-CAR-T showed superior therapeutic effects in solid tumors.
嵌合抗原受体T细胞(CAR-T)疗法得益于基因编辑技术与抗体工程的完美结合,在血液系统恶性肿瘤中显示出卓越的临床疗效。由于实体瘤的微环境和结构特征极其复杂,因此成为下一个挑战。靶向效率和持久性是目前CAR-T临床治疗中的瓶颈问题。除了药物和细胞因子外,生物材料还可以调节免疫反应,协助过继性CAR-T细胞发挥其功能。在本研究中,设计了一种超分子肽水凝胶表位疫苗,作为CAR-T细胞的制备培养基和储存库。自组装肽通过两亲性氨基酸和离子稳定剂的非共价相互作用形成纳米纤维支架。首先,互补肽偶联的疫苗表位和CAR-T靶点来自HER2蛋白的不同细胞外结构域,联合治疗提高了肿瘤抗原的扩散和靶向效率。表位水凝胶促进了CAR-T细胞的增殖、细胞毒性活性和淋巴细胞亚群转化。此外,超分子肽表位疫苗包裹的CAR-T(SPEV-CAR-T)通过水凝胶和CAR-T细胞的持续释放诱导内源性体液和细胞免疫反应,在体内小鼠模型中显示出优异的抗肿瘤效果。最重要的是,SPEV-CAR-T在全身免疫组织中诱导了中枢记忆细胞,解决了单一CAR-T疗法持久性差的问题。这种一体化水凝胶表位疫苗和CAR-T系统中主动免疫和被动免疫反应的整合与互补促进了内源性和外源性免疫反应的相继发生,促进了持续和特异性的肿瘤攻击。SPEV-CAR-T在实体瘤中显示出优异的治疗效果。